Traitement des métastases osseuses du cancer du rein

Annalisa Guida; Laurence Albiges

doi:10.1016/S0007-4551(18)30382-5

Traitement des métastases osseuses du cancer du rein

Translated title of the contribution: Treating patients with bone metastases from renal cell carcinoma

Annalisa Guida, Laurence Albiges

Research output: Contribution to journal › Article › peer-review

Abstract

Treating patients with bone metastases from renal cell carcinoma: Bone metastases (BMs) are common and cause morbidity in cancer patients. One third of metastatic renal cancer (mRCC) patients present metastatic disease to the bone. BMs cause severe complications such as fracture, spinal cord compression and pain requiring surgery or radiotherapy. Hypercalcaemia is a common feature in mRCC as well as an established poor prognosis factor. BMs impact negatively on prognosis and affect quality of life. Correct management of BMs from RCC requires a multimodal evaluation to optimize care and quality of life. In this review, we discuss current evidences on the role of systemic treatments in BMs management, bone-targeting agents benefits in skeletal-related events prevention and local therapeutic approaches to BM in mRCC. Define prognosis of systemic disease and identify the main goal of treatment are crucial for the selection of the best strategy.

Translated title of the contribution	Treating patients with bone metastases from renal cell carcinoma
Original language	French
Pages (from-to)	S268-S279
Journal	Bulletin du Cancer
Volume	105
DOIs	https://doi.org/10.1016/S0007-4551(18)30382-5
Publication status	Published - 1 Dec 2018

Access to Document

10.1016/S0007-4551(18)30382-5

Cite this

@article{201f70a64f48450d9887b7305387ca79,

title = "Traitement des m{\'e}tastases osseuses du cancer du rein",

abstract = "Treating patients with bone metastases from renal cell carcinoma: Bone metastases (BMs) are common and cause morbidity in cancer patients. One third of metastatic renal cancer (mRCC) patients present metastatic disease to the bone. BMs cause severe complications such as fracture, spinal cord compression and pain requiring surgery or radiotherapy. Hypercalcaemia is a common feature in mRCC as well as an established poor prognosis factor. BMs impact negatively on prognosis and affect quality of life. Correct management of BMs from RCC requires a multimodal evaluation to optimize care and quality of life. In this review, we discuss current evidences on the role of systemic treatments in BMs management, bone-targeting agents benefits in skeletal-related events prevention and local therapeutic approaches to BM in mRCC. Define prognosis of systemic disease and identify the main goal of treatment are crucial for the selection of the best strategy.",

keywords = "Bone metastases, Bone targetting, Local treatment, Systemic therapy, agents, mRCC",

author = "Annalisa Guida and Laurence Albiges",

note = "Publisher Copyright: {\textcopyright} 2018 Elsevier Masson SAS",

year = "2018",

month = dec,

day = "1",

doi = "10.1016/S0007-4551(18)30382-5",

language = "Fran{\c c}ais",

volume = "105",

pages = "S268--S279",

journal = "Bulletin du Cancer",

issn = "0007-4551",

}

TY - JOUR

T1 - Traitement des métastases osseuses du cancer du rein

AU - Guida, Annalisa

AU - Albiges, Laurence

PY - 2018/12/1

Y1 - 2018/12/1

N2 - Treating patients with bone metastases from renal cell carcinoma: Bone metastases (BMs) are common and cause morbidity in cancer patients. One third of metastatic renal cancer (mRCC) patients present metastatic disease to the bone. BMs cause severe complications such as fracture, spinal cord compression and pain requiring surgery or radiotherapy. Hypercalcaemia is a common feature in mRCC as well as an established poor prognosis factor. BMs impact negatively on prognosis and affect quality of life. Correct management of BMs from RCC requires a multimodal evaluation to optimize care and quality of life. In this review, we discuss current evidences on the role of systemic treatments in BMs management, bone-targeting agents benefits in skeletal-related events prevention and local therapeutic approaches to BM in mRCC. Define prognosis of systemic disease and identify the main goal of treatment are crucial for the selection of the best strategy.

AB - Treating patients with bone metastases from renal cell carcinoma: Bone metastases (BMs) are common and cause morbidity in cancer patients. One third of metastatic renal cancer (mRCC) patients present metastatic disease to the bone. BMs cause severe complications such as fracture, spinal cord compression and pain requiring surgery or radiotherapy. Hypercalcaemia is a common feature in mRCC as well as an established poor prognosis factor. BMs impact negatively on prognosis and affect quality of life. Correct management of BMs from RCC requires a multimodal evaluation to optimize care and quality of life. In this review, we discuss current evidences on the role of systemic treatments in BMs management, bone-targeting agents benefits in skeletal-related events prevention and local therapeutic approaches to BM in mRCC. Define prognosis of systemic disease and identify the main goal of treatment are crucial for the selection of the best strategy.

KW - Bone metastases

KW - Bone targetting

KW - Local treatment

KW - Systemic therapy

KW - agents

KW - mRCC

UR - http://www.scopus.com/inward/record.url?scp=85059091234&partnerID=8YFLogxK

U2 - 10.1016/S0007-4551(18)30382-5

DO - 10.1016/S0007-4551(18)30382-5

M3 - Article

C2 - 30595156

AN - SCOPUS:85059091234

SN - 0007-4551

VL - 105

SP - S268-S279

JO - Bulletin du Cancer

JF - Bulletin du Cancer

ER -

Traitement des métastases osseuses du cancer du rein

Abstract

Access to Document

Other files and links

Cite this